Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Lockshin

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of the American Academy of Dermatology|February 26, 2018
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasisBenjamin Lockshin, Yevgeniy Balagula, Joseph F Merola
Seminars in Arthritis and Rheumatism|April 2, 2017
Switching biologics in the treatment of psoriatic arthritisJoseph F Merola, Benjamin Lockshin, Elinor A Mody
Journal of Drugs in Dermatology : JDD|November 16, 2020
Therapies for Psoriasis: Clinical and Economic ComparisonsAlbert Marchetti, Tina Bhutani, Benjamin Lockshin, et al.
Journal of Dermatological Science|December 3, 2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL studyBruce Strober, Ali Alikhan, Benjamin Lockshin, et al.
Acta Dermato-Venereologica|February 13, 2024
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 TrialMichael J Cork, Benjamin Lockshin, Andreas Pinter, et al.
Dermatology and Therapy|February 27, 2022
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or GuselkumabAndrew Blauvelt, Russel Burge, Gaia Gallo, et al.
American Journal of Clinical Dermatology|October 16, 2019
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational StudyPhillip J Mease, Clive Liu, Evan Siegel, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus PanelMilaan Shah, Joshua Burshtein, Danny Zakria, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of the American Academy of Dermatology|February 26, 2018
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasisBenjamin Lockshin, Yevgeniy Balagula, Joseph F Merola
Seminars in Arthritis and Rheumatism|April 2, 2017
Switching biologics in the treatment of psoriatic arthritisJoseph F Merola, Benjamin Lockshin, Elinor A Mody
Journal of Drugs in Dermatology : JDD|November 16, 2020
Therapies for Psoriasis: Clinical and Economic ComparisonsAlbert Marchetti, Tina Bhutani, Benjamin Lockshin, et al.
Journal of Dermatological Science|December 3, 2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL studyBruce Strober, Ali Alikhan, Benjamin Lockshin, et al.
Acta Dermato-Venereologica|February 13, 2024
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 TrialMichael J Cork, Benjamin Lockshin, Andreas Pinter, et al.
Dermatology and Therapy|February 27, 2022
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or GuselkumabAndrew Blauvelt, Russel Burge, Gaia Gallo, et al.
American Journal of Clinical Dermatology|October 16, 2019
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational StudyPhillip J Mease, Clive Liu, Evan Siegel, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus PanelMilaan Shah, Joshua Burshtein, Danny Zakria, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Pageof 3